Lutetium oxodotreotide with octreotide for treating previously untreated advanced gastroenteropancreatic neuroendocrine tumour

Lutetium oxodotreotide with octreotide is currently in clinical development for the treatment of patients with metastatic or advanced grade 2 or 3 gastroenteropancreatic neuroendocrine tumour (GEP-NET). A neuroendocrine tumour (NET) is a rare tumour that can develop in many different organs of the body. It affects the cells that release hormones into the bloodstream called neuroendocrine cells. GEP-NET is a rare type of tumour that can grow in various areas of the gut, such as the stomach, small intestine, rectum, colon, appendix, or pancreas. Metastatic or advanced cancer is cancer that had spread around the body from the area it started. GEP-NETs are difficult to diagnose and treat. In addition, there are limited treatment options available for patients with advanced GEP-NET, beyond standard therapy with somatostatin analogues.